Automated Algorithm Based Analysis of Phonocardiograms of Newborns

Status Completed

Clinical Trial Summary

The purpose of this double-blind pivotal clinical utility study is to determine on a large patient population whether heart murmurs can be reliably detected with high sensitivity and specificity using a locked, automated algorithm-based phonocardiogram analysis (also referred to as computer aided auscultation (CAA)).

Each patient is auscultated and diagnosed independently by a medical specialist. Additionally, for each patient, an echocardiogram is performed as the gold-standard for determining heart pathologies. The CAA results are compared to the findings of the medical professionals as well as to the echocardiogram findings.

Hypothesis: The specific (locked) CAA algorithms used in this study are able to automatically diagnose pathological heart murmurs in premature babies and newborns with at least the same accuracy as experienced medical specialists.

Clinical Trial Description

The following registry procedures and quality factors have been implemented:

- Quality assurance plan, including

- data validation

- proper registration procedures

- regular site monitoring

- regular auditing

- Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.

- Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (medical records and paper case report forms).

- Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management.

- Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect.

- Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.

- Plan for missing data to address situations where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02105480
Study type	Observational [Patient Registry]
Source	CSD Labs GmbH
Contact
Status	Completed
Phase
Start date	November 2013
Completion date	January 18, 2017

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02499419` - Exercise Capacity Evaluation in Patients With Non-rheumatic Mitral Valve Prolapse (MVP)	N/A
Completed	`NCT02512341` - Automatic Differentiation of Innocent and Pathologic Murmurs in Pediatrics
Enrolling by invitation	`NCT04067635` - Primary Mitral Regurgitation Repair
Recruiting	`NCT06378996` - Arrhythmic Mitral Valve Prolapse Detection Using Long-term Ambulatory Rhythm Monitoring	N/A
Terminated	`NCT03285724` - Safety and Performance Study of the Harpoon Mitral Valve Repair System	N/A
Recruiting	`NCT03506217` - Using Pulse Counter Vigileo-Flotrac System in Transapical Off-pump Minimally Invasive Mitral Valve Repair
Completed	`NCT00665301` - Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000	N/A
Not yet recruiting	`NCT04299334` - Neochordae Technique in Mitral Valve Repair	Phase 1
Completed	`NCT03470155` - Operative Mitral Valve Reconstruction in Functional mv Insufficiency With Reduced Systolic Ventricle Function
Recruiting	`NCT06341166` - Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse
Completed	`NCT04231903` - Myocardial Protection in Minimally Invasive Mitral Valve Surgery
Not yet recruiting	`NCT03609931` - Patient Specific Mitral Valve Modeling for Surgical Planning and Training
Recruiting	`NCT05631730` - Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse	Phase 3
Recruiting	`NCT02552771` - The Canadian Mitral Research Alliance (CAMRA) Trial CardioLink-2	N/A
Recruiting	`NCT01719211` - Genetic Basis of Mitral Valve Prolapse
Recruiting	`NCT06255457` - Arrhythmogenic Mitral Valve Disease in Patients Undergoing Mitral Valve Surgery
Recruiting	`NCT04190602` - Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System
Recruiting	`NCT03113552` - Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty
Completed	`NCT02771275` - Safety and Early Feasibility Study of the Harpoon Medical Device (EFS)	N/A
Recruiting	`NCT05562804` - Mitral Valve Prolapse, Arrhythmias and Mitral Valve Surgery

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.